Biomarker discovery and development are popular for detecting the subtle diseases.
However, biomarkers are needed to be validated and approved, and even fewer are ever …

Glioblastoma (GBM), an aggressive high-grade glial tumor, is resistant to therapy and has a
poor prognosis due to its universal recurrence rate. GBM cells interact with the non-cellular …

Spatial transcriptomics is a novel technique that provides RNA-expression data with tissue-
contextual annotations. Quality assessments of such techniques using end-user generated …

Gliomas represent the most common malignant primary brain tumors, and a high-grade
subset of these tumors including glioblastoma are particularly refractory to current standard …

Simple Summary Glioblastoma (GBM) is considered the deadliest brain tumor; with patients
displaying a high incidence of relapse and a 3-year survival of only 3–5%. For these …

Albumin-based hydrogels have emerged as promising nanoparticle systems for the effective
delivery of hydrophobic anticancer drugs. Anti-cancer drugs often cause some adverse …

Glioblastoma (GB) is a malignant glioma associated with a mean overall survival of 12 to 18
months, even with optimal treatment, due to its high relapse rate and treatment resistance …

Brain metastases are the most common brain malignancy. This review discusses the studies
presented at the third annual meeting of the Melanoma Research Foundation in the context …

Glioblastoma (GBM) remains a challenge in Neuro‐oncology, with a poor prognosis
showing only a 5% survival rate beyond two years. This is primarily due to its …

Abstract Background Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic
disorder that affects nearly 1 in 3000 infants. Neurofibromin inactivation and N F1 gene …